AN2 Therapeutics' Q4 net loss widens on higher R&D expenses

AN2 Therapeutics

17/03/2026 20:09

Overview

US biopharmaceutical firm's Q4 net loss widened yr/yr amid higher operating expenses

Company secured $40 mln private placement in March 2026, extending cash runway into 2029

AN2 advancing Phase 2 trials for polycythemia vera, M. abscessus lung disease, and Chagas disease

Outlook

Company expects to initiate three Phase 2 studies in 2026, with data readouts into 2027

AN2 plans to advance two oncology candidates into development in 2026

Company projects cash runway into 2029 under current operating plan

Result Drivers

HIGHER R&D SPENDING - Q4 R&D expenses rose yr/yr due to increased personnel, preclinical, research, chemistry manufacturing, and facilities costs, partially offset by lower clinical trial expenses after EBO-301 termination

LOWER G&A EXPENSES - Q4 G&A expenses fell yr/yr due to decreased professional and personnel-related costs

DECLINING INTEREST INCOME - Q4 interest income decreased yr/yr due to lower cash, cash equivalents and investment balances, and lower interest rates

Company press release: ID:nBw58vgJMa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 EPS
-$0.29
Q4 Net Income
-$8.71 mln
Q4 Income From Operations
-$9.32 mln
Q4 Operating Expenses
$9.32 mln


Analyst Coverage

The one available analyst rating on the shares is "hold"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for AN2 Therapeutics Inc is $1.00, about 78.7% below its March 16 closing price of $4.69

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)